Kaiser Health News
When Democrats pushed through a two-year expansion of the Affordable Care Act in the COVID-relief bill this month, many people celebrated the part that will make health insurance more affordable for more Americans.
“We need to take care of the problem everywhere to be able to take care of it anywhere,” says Dr. Mark Feinberg, president and CEO of the International AIDS Vaccine Initiative.
Public advocates say that more sustained funding will be needed over the next decade and beyond to address long-festering problems.
With three vaccines — Pfizer-BioNTech, Moderna and Johnson & Johnson — now authorized for emergency use in the United States, there seems to be hope that the pandemic’s end may be in sight.
Hundreds of thousands of people around the world are experiencing what is being called “long COVID” — a pattern of prolonged symptoms following an acute bout of the disease.
As President Joe Biden’s pandemic relief package steams through Congress, Democrats have hitched a ride for a top health care priority: strengthening the Affordable Care Act with some of the most significant changes to insurance affordability in more than a decade.
Scientists say unprepared immune cells appear to be responding to the coronavirus with a devastating release of chemicals, inflicting damage that may endure long after the threat has been eliminated.
Federal rules around who can be told about the variant cases are so confusing that public health officials may merely know the county where a case has emerged.
This lung transplant case may be the first proven of COVID-19 in the U.S. in which the virus was transmitted via an organ transplant.